Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 4,009
Out of 5,135 analysts
59
Total ratings
33.33%
Success rate
-14.03%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $2.33 | -14.16% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $7.03 | +28.02% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.18 | +493.22% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.17 | +151.05% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.32 | -24.24% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $7.83 | +155.43% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.45 | +185.71% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.83 | +239.43% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.72 | +108.33% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $476.05 | -30.68% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $66.98 | -13.41% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $39.82 | -37.22% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.86 | +253.54% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $4.60 | +30.43% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $35.76 | -46.87% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $73.06 | +64.25% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $6.80 | +635.29% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.76 | +153.81% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $2.33
Upside: -14.16%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $7.03
Upside: +28.02%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.18
Upside: +493.22%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.17
Upside: +151.05%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.32
Upside: -24.24%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $7.83
Upside: +155.43%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.45
Upside: +185.71%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.83
Upside: +239.43%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.72
Upside: +108.33%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $476.05
Upside: -30.68%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $66.98
Upside: -13.41%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $39.82
Upside: -37.22%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.86
Upside: +253.54%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $4.60
Upside: +30.43%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $35.76
Upside: -46.87%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $73.06
Upside: +64.25%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $6.80
Upside: +635.29%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.76
Upside: +153.81%